Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis

Clinical Rheumatology

Volumn 36, Issue 2, 2017, Pages 469-475

  Ceribelli, Angela ^a   Isailovic, Natasa ^a   De Santis, Maria ^a   Generali, Elena ^a   Fredi, Micaela ^b   Cavazzana, Ilaria ^b   Franceschini, Franco ^b   Cantarini, Luca ^c   Satoh, Minoru ^d   Selmi, Carlo ^a,e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Biomarkers; Cancer; Idiopathic inflammatory myositis; Immunoprecipitation

Indexed keywords

AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1 AUTOANTIBODY; NXP2 AUTOANTIBODY; RNA; STEROID; TIF1 AUTOANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ANTISYNTHETASE SYNDROME; AREA UNDER THE CURVE RATIO; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; ITALIAN (CITIZEN); MALE; MEDICAL RECORD REVIEW; POLYMYOSITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; STEROID THERAPY; VERY ELDERLY; WESTERN BLOTTING; ADOLESCENT; BLOOD; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; IMMUNOLOGY; INFLAMMATION; ITALY; MIDDLE AGED; MYOSITIS; NEOPLASM; RECEIVER OPERATING CHARACTERISTIC; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOMARKERS; COHORT STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOPRECIPITATION; INFLAMMATION; ITALY; MALE; MIDDLE AGED; MYOSITIS; NEOPLASMS; POLYMYOSITIS; PREDICTIVE VALUE OF TESTS; RISK; RNA; ROC CURVE; YOUNG ADULT;

EID: 84991794162     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3453-0     Document Type: Article

References (24)

1. Lundberg IE et al (2016) Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 280(1):39–51
2. Ceribelli A. et al. (2016) The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review. Clin Rev Allergy Immunol
3. Gunawardena H. (2015) The Clinical Features of Myositis-Associated Autoantibodies: a Review. Clin Rev Allergy Immunol
4. Satoh M. et al. (2015) A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol
5. Targoff IN (1992) Autoantibodies in polymyositis. Rheum Dis Clin N Am 18(2):455–482
6. Ceribelli A et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32(6):891–897
7. Satoh M et al (2012) Autoantibodies to transcription intermediary factor TIF1beta associated with dermatomyositis. Arthritis Res Ther 14(2):R79
8. Fiorentino DF et al (2016) PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjogren's syndrome. Ann Rheum Dis 75(6):1145–1151
9. Ceribelli A et al (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37(10):2071–2075
10. Ceribelli A et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14(2):R97
11. Yamasaki Y et al (2016) Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol 26(3):403–409
12. Palaniappan P, Lionel AP, Kumar S (2014) Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate. J Clin Rheumatol 20(8):454–455
13. Rider LG et al (2013) The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(4):223–243
14. Ichimura Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71(5):710–713
15. Tiniakou, E. and A.L. Mammen, Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. Clin Rev Allergy Immunol, 2015.
16. Selva-O'Callaghan A et al (2010) Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 22(6):627–632
17. Targoff IN et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689
18. Gunawardena H et al (2008) Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47(3):324–328
19. Kaji K et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46(1):25–28
20. Chinoy H et al (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345–1349
21. Fujikawa K et al (2009) Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 38(4):263–267
22. Selmi C et al (2016) Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev 15(2):162–166
23. Cavazzana I et al (2016) Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1–5
24. Chan EK et al (2016) Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 25(8):797–804